Infant Bacterial Therapeutics Ab Class BOMXSTO: IBT_B

Infant Bacterial Announces Phase III IBP-9414 Study Results

· Issued by Infant Bacterial Therapeutics Ab Class B

Infant Bacterial Therapeutics AB OMXSTO:IBT_B:

  • ANNOUNCES PHASE III STUDY RESULTS PUBLISHED IN PEDIATRIC RESEARCH

  • PHASE III STUDY SHOWS 27% MORTALITY REDUCTION WITH IBP-9414

  • TREATMENT DESIGNATED AS 'BREAKTHROUGH THERAPY' AND 'RARE PAEDIATRIC DISEASE'

  • STUDY CONCLUDES IBP-9414 REDUCES MORTALITY AND NECROTIZING ENTEROCOLITIS

Earlier from Infant Bacterial Therapeutics Ab Class B

All Infant Bacterial Therapeutics Ab Class B news releases